20
Participants
Start Date
January 8, 2024
Primary Completion Date
January 31, 2025
Study Completion Date
June 30, 2025
Psilocybin
"Phase 1 (week 1): all enrolled participants will take a single 1mg oral dose of psilocybin once per day on Monday and Thursday. If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 2 for week 2.~Phase 2: The participant will take a single 1mg oral dose of psilocybin once per day for 5 consecutive days (Monday to Friday). If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 3 for week 3.~Phase 3: The participant will take two 1mg oral doses (2mg total) of psilocybin once per day for 5 consecutive days (Monday to Friday). If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 4 for week 4.~Phase 4 (maximum allowable dose): The participant will take three 1mg oral doses (3mg total) of psilocybin once per day for 5 consecutive days (Monday to Friday)."
RECRUITING
The Ottawa Hospital, Ottawa
RECRUITING
Bruyere Continuing Care, Ottawa
Lead Sponsor
Collaborators (1)
Bruyère Health Research Institute.
OTHER
The Ottawa Hospital
OTHER
St. Joseph's Healthcare Hamilton
OTHER
CHU de Quebec-Universite Laval
OTHER
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
OTHER
Jewish General Hospital
OTHER
William Osler Health System
OTHER
Queen's University
OTHER
Ottawa Hospital Research Institute
OTHER